79,889 followers
$AGN another ophthalmology deal after Oculeve and AqueSys Ph2 data https://t.co/LtT7Yfz6LA https://t.co/0s1h9SaKyW https://t.co/7pIMK1T4jc
$AGN another ophthalmology deal after Oculeve and AqueSys Ph2 data https://t.co/LtT7Yfz6LA https://t.co/0s1h9SaKyW https://t.co/7pIMK1T4jc
Mimetogen Pharmaceuticals publishes phase II data on their tyrosine kinase TrkA receptor agonist MIM-D3 http://t.co/d0lE7Vta8G
Mimetogen Pharmaceuticals publishes phase II data on their tyrosine kinase TrkA receptor agonist MIM-D3 http://t.co/d0lE7Vta8G
Mimetogen Pharmaceuticals publishes phase II data on their tyrosine kinase TrkA receptor agonist MIM-D3 http://t.co/d0lE7Vta8G
Safety and efficacy of MIM D3 ophthalmic solutions in a randomized placebo controlled Phase 2 clinical trial i... http://t.co/jbd15J2qG2